This Notice of Special Interest (NOSI) is to encourage applications to support the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science. Funding opportunities are available for scientists at early career stages including graduate student, postdoctoral, early career, and midcareer-level investigators.

Background

There is an urgent and critical need for a substantial increase in the number of scientists pursuing research in addiction medicine. Supporting creative individuals from a variety of backgrounds and disciplines who bring enthusiasm and dedication to thisenterprise will ensure continuous and sustained progresstowards developing effective treatments for substance use disorder and its associated medical consequences, while also bolstering the addiction medicine research workforce by paving the way for scientists to build a successful career in this area of critical importance to the nation.

Research Objectives

This NOSI announces that the National Institute on Drug Abuse (NIDA), Division of Therapeutics and Medical Consequences (DTMC) intends to bolster the addiction medicine research workforce by providing individuals aspiring to initiate and/or advance a career in research focusing on treatment development, pharmacotherapy, and/or studying the medical consequences related to substance use/substance use disorder with training opportunities, resources, and mentorship. Specifically, research training and career development applications are encouraged in the areas of drug discovery and development, preclinical and clinical trials of medications and immunotherapies, therapeutic devices, digital eHealth development, and behavioral therapies.

The Research Training and Career Development awards in the following research topics include but are not limited to:

1. Drug discovery and translational research for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate misuse;
2. Preclinical Addition Treatment Discovery Program with the goal of identifying potential medications to treat drug dependence disorders;
3. Phase I clinical trials or Phase II clinical trials for novel treatments of substance use disorder;
4. Development of digital eHealth applications, devices, and monitoring units to pursue translational or clinical studies for treatment adherence or devices to treat substance use disorders;
5. Development of behavioral therapies for substance use disorders;
6. Research on medical consequences of substance use such as co-occurring infections including HIV, HCV, and others in humans (special studies in women, minorities, children/adolescents and underserved populations are encouraged).

Application and Submission Information

This Notice applies to due dates on or after June 12, 2020 and expires on September 8, 2023.

Applications in response to this NOSI must be submitted using one of the following target Funding Opportunity Announcements (FOAs) or their reissued equivalents.

Activity Code	FOA
F30	PA--19-191, PA-19-192 Ruth L. Kirschstein Individual Predoctoral NRSA for MD/PhD and other Dual Degree Fellowships
F31	PA-19-195 Ruth L. Kirschstein Predoctoral Individual National Research Service Award
F31	PA-19-196 Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31 - Diversity)
F32	PA-19-188 Ruth L. Kirschstein Postdoctoral Individual National Research Service Award
K01	PA-19-126 Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
K01	PA-19-127 Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)
K01	PA-19-084 Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)
K02	PA-19-132 Independent Research Scientist Development Award (Independent Clinical Trial Not Allowed)
K02	PA-19-131 Independent Research Scientist Development Award (Independent Clinical Trial Required)
K02	PA-19-085 Independent Research Scientist Development Award (Independent Basic Experimental Studies with Humans Required)
K08	PA-19-116 Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)
K08	PA-19-117 Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
K08	PA-19-086 Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)
K23	PA-19-118 Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
K23	PA-19-119 Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)
K23	PA-19-087 Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)
K99/R00	PA-19-129 NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
K99/R00	PA-19-130 NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed)
K99/R00	PA-19-090 NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required

All instructions in the SF424 (R&R) Application Guide and the listed funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-DA-20-037” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.